Abstract
Novel micelle-forming poly(ethylene oxide)- block-poly(ε-caprolactone) (PEO- b-PCL) block copolymers bearing doxorubicin (DOX) side groups (PEO- b-P(CL-DOX)) on the PCL block were synthesized. Prepared block copolymers were characterized, assembled to polymeric micellar drug conjugates and assessed for the level of DOX release at pH 7.4 and pH 5.0 using a dialysis membrane to separate released and conjugated drug. The possibility for the degradation of PCL backbone for PEO- b-P(CL-DOX) micelles was investigated using gel permeation chromatography. Micelle-forming DOX conjugate did not show any signs of DOX release at 37 °C within 72 h of incubation at both pHs, but revealed signs of poly(ester) core degradation at pH 5.0. In further studies, PEO- b-PCL micelles bearing benzyl, carboxyl or DOX groups in the core were also used as micellar nano-containers for the physical encapsulation of DOX, where maximum level of drug-loading and control over the rate of DOX release was achieved by polymeric micelles containing benzyl groups in their core, i.e., PEO- b-poly(α-benzylcarboxylate-ε-caprolactone) (PEO- b-PBCL) micelles. The in vitro cytotoxicity of chemically conjugated DOX as part of PEO- b-P(CL-DOX) and physically encapsulated DOX in PEO- b-PBCL against B16F10 murine melanoma cells was assessed and compared to that of free DOX. Consistent with the results of in vitro release study, cytotoxicity of micellar PEO- b-P(CL-DOX) conjugate (IC 50 of 3.65 μg/mL) was lower than that of free and physically encapsulated DOX in PEO- b-PBCL (IC 50 of 0.09 and 3.07 μg/mL, respectively) after 24 h of incubation. After 48 h of incubation, the cytotoxicity of conjugated DOX (IC 50 of 0.50 μg/mL) was still lower than the cytotoxicity of free DOX (IC 50 of 0.03 μg/mL), but surpassed that of physically encapsulated DOX in PEO- b-PBCL (IC 50 of 1.54 μg/mL). The results point to a potential for PEO- b-P(CL-DOX) and PEO- b-PBCL as novel polymeric micellar drug conjugates and nano-containers bearing hydrolyzable cores for DOX delivery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Pharmaceutics and Biopharmaceutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.